Technical Analysis for CERC - Cerecor Inc.

Grade Last Price % Change Price Change
grade B 5.59 -5.57% -0.33
CERC closed down 5.57 percent on Friday, March 22, 2019, on 40 percent of normal volume.

Earnings due: Apr 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical CERC trend table...

Date Alert Name Type % Chg
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 20 DMA Resistance Bearish -5.57%
Mar 21 Wide Bands Range Expansion -5.57%
Mar 20 20 DMA Resistance Bearish -4.44%
Mar 20 Wide Bands Range Expansion -4.44%
Mar 20 Oversold Stochastic Weakness -4.44%
Mar 19 Spinning Top Other -1.93%
Mar 19 Wide Bands Range Expansion -1.93%
Mar 19 Oversold Stochastic Weakness -1.93%
Mar 18 Stochastic Buy Signal Bullish -1.93%

Older signals for CERC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Chemistry Biopharmaceutical Disorders Organic Chemistry Depression Major Depressive Disorder Antidepressants Piperidines Pyrrolidines Nmda Receptor Antagonists
Is CERC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.65
52 Week Low 2.71
Average Volume 137,199
200-Day Moving Average 4.509
50-Day Moving Average 5.3437
20-Day Moving Average 5.937
10-Day Moving Average 5.653
Average True Range 0.3828
ADX 25.76
+DI 24.6789
-DI 18.5754
Chandelier Exit (Long, 3 ATRs ) 6.5016
Chandelier Exit (Short, 3 ATRs ) 6.2784
Upper Bollinger Band 7.0591
Lower Bollinger Band 4.8149
Percent B (%b) 0.35
BandWidth 37.800236
MACD Line 0.103
MACD Signal Line 0.1516
MACD Histogram -0.0485
Fundamentals Value
Market Cap 145.63 Million
Num Shares 26.1 Million
EPS -1.12
Price-to-Earnings (P/E) Ratio -4.99
Price-to-Sales 24.44
Price-to-Book 4.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.15
Resistance 3 (R3) 6.19 6.05 6.06
Resistance 2 (R2) 6.05 5.90 6.03 6.03
Resistance 1 (R1) 5.82 5.81 5.75 5.78 6.00
Pivot Point 5.67 5.67 5.63 5.65 5.67
Support 1 (S1) 5.44 5.53 5.37 5.40 5.18
Support 2 (S2) 5.30 5.44 5.28 5.15
Support 3 (S3) 5.07 5.30 5.12
Support 4 (S4) 5.03